Opinion|Videos|March 13, 2025
Applying Results From PEACE-3 to Your Patient Population
Panelists discuss how adapting the PEACE-3 protocol to real-world US patient populations requires careful consideration of broader patient demographics, comorbidities, and prior treatment histories than were represented in the trial’s relatively strict eligibility criteria.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- The eligibility criteria of the PEACE-3 trial are different from the patient demographics we see here in the US; how would you go about applying the PEACE-3 protocol to your patient population?
- How do the PEACE-3 trial results compare with current first-line treatment options for metastatic castration-resistant prostate cancer?
Advertisement
Related to this article
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
FDA updates in urology: September 2026
3
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
4
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
5